Compare GSK Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PFIZER - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PFIZER GSK PHARMA/
PFIZER
 
P/E (TTM) x 238.6 44.0 541.7% View Chart
P/BV x 12.0 7.6 157.4% View Chart
Dividend Yield % 1.3 0.4 294.2%  

Financials

 GSK PHARMA   PFIZER
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
PFIZER
Mar-19
GSK PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,5953,840 93.6%   
Low Rs1,2532,080 60.2%   
Sales per share (Unadj.) Rs184.7455.0 40.6%  
Earnings per share (Unadj.) Rs26.393.8 28.0%  
Cash flow per share (Unadj.) Rs29.2109.4 26.7%  
Dividends per share (Unadj.) Rs20.0022.50 88.9%  
Dividend yield (eoy) %0.80.8 108.5%  
Book value per share (Unadj.) Rs126.3658.2 19.2%  
Shares outstanding (eoy) m169.4045.75 370.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.16.5 201.8%   
Avg P/E ratio x92.231.6 292.1%  
P/CF ratio (eoy) x83.127.1 307.2%  
Price / Book Value ratio x19.24.5 426.7%  
Dividend payout %76.124.0 317.0%   
Avg Mkt Cap Rs m410,626135,420 303.2%   
No. of employees `0005.02.6 188.5%   
Total wages/salary Rs m5,3723,238 165.9%   
Avg. sales/employee Rs Th6,306.77,911.4 79.7%   
Avg. wages/employee Rs Th1,083.11,230.9 88.0%   
Avg. net profit/employee Rs Th898.01,630.7 55.1%   
INCOME DATA
Net Sales Rs m31,28120,815 150.3%  
Other income Rs m1,0231,674 61.1%   
Total revenues Rs m32,30422,489 143.6%   
Gross profit Rs m6,0095,712 105.2%  
Depreciation Rs m486714 68.1%   
Interest Rs m673 8.2%   
Profit before tax Rs m6,5406,599 99.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3732,309 102.8%   
Profit after tax Rs m4,4544,291 103.8%  
Gross profit margin %19.227.4 70.0%  
Effective tax rate %36.335.0 103.7%   
Net profit margin %14.220.6 69.1%  
BALANCE SHEET DATA
Current assets Rs m20,06127,167 73.8%   
Current liabilities Rs m14,5438,917 163.1%   
Net working cap to sales %17.687.7 20.1%  
Current ratio x1.43.0 45.3%  
Inventory Days Days5768 83.7%  
Debtors Days Days1430 46.7%  
Net fixed assets Rs m14,3438,862 161.8%   
Share capital Rs m1,694458 370.3%   
"Free" reserves Rs m19,70429,656 66.4%   
Net worth Rs m21,39830,113 71.1%   
Long term debt Rs m225 8.0%   
Total assets Rs m39,11339,400 99.3%  
Interest coverage x1,091.091.5 1,192.1%   
Debt to equity ratio x00 11.3%  
Sales to assets ratio x0.80.5 151.4%   
Return on assets %11.411.1 103.0%  
Return on equity %20.814.2 146.1%  
Return on capital %31.922.1 144.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m534428 124.7%   
Fx outflow Rs m7,091786 901.7%   
Net fx Rs m-6,557-358 1,831.1%   
CASH FLOW
From Operations Rs m3,994978 408.3%  
From Investments Rs m-1,433351 -408.1%  
From Financial Activity Rs m-3,584-1,099 326.2%  
Net Cashflow Rs m-1,023231 -443.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 63.9 79.3%  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 4.9 485.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.7 65.0%  
Shareholders   102,036 85,207 119.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Equitas Small Finance Bank IPO, LIC Q2 Stake Hike in Companies, and Top Buzzing Stocks Today(Pre-Open)

It was indeed a volatile trading day for share markets in India yesterday. After staging a gap-up opening, Indian share markets reversed gains.

Related Views on News

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Oct 21, 2020 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - WYETH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS